TY - JOUR
T1 - Physical component quality of life reflects the impact of time and moderate chronic kidney disease, unlike SF-6D utility and mental component SF-36 quality of life
T2 - An AusDiab analysis
AU - Wong, Muh G.
AU - Ninomiya, Toshiharu
AU - Liyanage, Thaminda
AU - Sukkar, Louisa
AU - Hirakawa, Yoichiro
AU - Wang, Ying
AU - Wyld, Melanie L.R.
AU - Morton, Rachel L.
AU - Chadban, Steven
AU - Howard, Kirsten
AU - Jardine, Meg J.
N1 - Funding Information:
MGW has received honorarium for scientific lectures from AstraZeneca, Amgen and Baxter. TL and LS have no conflicts of interests to declare. MJJ is supported by a co-funded National Health and Medical Research Council Career Development Fellowship and National Heart Foundation Future Leader Fellowship; is responsible for research projects that have received unrestricted funding from Gambro, Baxter, CSL, Amgen, Eli Lilly, and Merck; has served on advisory boards and/or spoken at scientific meetings sponsored by Boehringer Ingelheim, Baxter, Amgen and Roche; and directs honoraria to clinical research programmes.
Funding Information:
MGW is supported by Diabetes Australian Research Trust Millennium Grant. TL and LS were supported by Australian Postgraduate Award. YW was supported by John Chalmers Servier Post-Doctoral Fellowship. MLRW was supported by a NHMRC Post-Graduate Scholarship. RLM was supported by an Australian NHMRC Early Career Researcher Fellowship. The AusDiab study, co-ordinated by the Baker IDI Heart and Diabetes Institute, gratefully acknowledges the generous support given by the National Health and Medical Research Council (NHMRC grant 233200), Australian Government Department of Health and Ageing, Amgen, Abbott Australasia, Alphapharm, AstraZeneca, Bristol-Myers Squibb, City Health Centre-Diabetes Service – Canberra, Department of Health and Community Services – Northern Territory, Department of Health and Human Services – Tasmania, Department of Health – New South Wales, Department of Health – Western Australia, Department of Health – South Australia, Department of Human Services – Victoria, Diabetes Australia, Diabetes Australia Northern Territory, Eli Lilly Australia, Estate of the Late Edward Wilson, Glaxo-SmithKline, Jack Brockhoff Foundation, Janssen-Cilag, Kidney Health Australia, Marian & FH Flack Trust, Menzies Research Institute, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk Pharmaceuticals, Pfizer, Pratt Foundation, Queensland Health, Roche Diagnostics Australia, Royal Prince Alfred Hospital, Sydney, Sanofi Aventis and Sanofi Synthelabo. The AusDiab study co-ordinators are also grateful to A. Allman, B. Atkins, S. Bennett, A. Bonney, S. Chadban, M. de Courten, M. Dalton, D. Dunstan, T. Dwyer, H. Jahangir, D. Jolley, D. McCarty, A. Meehan, N. Meinig, S. Murray, K. O'Dea, K. Polkinghorne, P. Phillips, C. Reid, A. Stewart, R. Tapp, H. Taylor, T. Whalen, F. Wilson and P. Zimmet for their invaluable contribution to the setup and field activities of AusDiab.
Funding Information:
MGW is supported by Diabetes Australian Research Trust Millennium Grant. TL and LS were supported by Australian Postgraduate Award. YW was supported by John Chalmers Servier Post-Doctoral Fellowship. MLRW was supported by a NHMRC Post-Graduate Scholarship. RLM was supported by an Australian NHMRC Early Career Researcher Fellowship. The AusDiab study, co-ordinated by the Baker IDI Heart and Diabetes Institute, gratefully acknowledges the generous support given by the National Health and Medical Research Council (NHMRC grant 233200), Australian Government Department of Health and Ageing, Amgen, Abbott Australasia, Alphapharm, AstraZeneca, Bristol-Myers Squibb, City Health Centre-Diabetes Service – Canberra, Department of Health and Community Services – Northern Territory, Department of Health and Human Services – Tasmania, Department of Health – New South Wales, Department of Health – Western Australia, Department of Health – South Australia, Department of Human Services – Victoria, Diabetes Australia, Diabetes Australia Northern Territory, Eli Lilly Australia, Estate of the Late Edward Wilson, Glaxo-SmithK-line, Jack Brockhoff Foundation, Janssen-Cilag, Kidney Health Australia, Marian & FH Flack Trust, Menzies Research Institute, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk Pharmaceuticals, Pfizer, Pratt Foundation, Queensland Health, Roche Diagnostics Australia, Royal Prince Alfred Hospital, Sydney, Sanofi Aventis and Sanofi Synthelabo. The AusDiab study co-ordinators are also grateful to A. Allman, B. Atkins, S. Bennett, A. Bonney, S. Chadban, M. de Courten, M. Dalton, D. Dunstan, T. Dwyer, H. Jahangir, D. Jolley, D. McCarty, A. Meehan, N. Meinig, S. Murray, K. O’Dea, K. Polkinghorne, P. Phillips, C. Reid, A. Stewart, R. Tapp, H. Taylor, T. Whalen, F. Wilson and P. Zimmet for their invaluable contribution to the setup and field activities of AusDiab.
Publisher Copyright:
© 2018 Asian Pacific Society of Nephrology
PY - 2019/6
Y1 - 2019/6
N2 - Aim: Assessing the impact of interventions on the patient experience requires measures that are plausibly responsive to change. In a community cohort of people with and without chronic kidney disease (CKD) markers at baseline, we aimed to evaluate change in commonly used measures of quality of life (QOL) over the passage of 5 years. Methods: Included were 6400 participants in the Australian Diabetes, Obesity and Lifestyle (AusDiab) surveys with baseline and 5-year CKD and QOL measures. Changes in SF-6D utility, and the Medical Outcomes Study 36-Item Short Form (SF-36) physical (PCS) and mental (MCS) component summary scores, were evaluated with regression analyses according to the baseline presence of reduced estimated glomerular filtration rate (eGFR) (CKD-Epidemiology Collaboration eGFR ≤60 m/min per 1.73 m 2 ) or albuminuria (urine albumin:creatinine ratio ≥3.4 mg/mmol). Results: At baseline, eGFR was reduced in 2.4% of participants and 5.1% had albuminuria. Participants with reduced eGFR had a lower SF-6D and PCS, and those with albuminuria a lower PCS, compared with those without, but the differences were explained by known confounders. MCS scores were not affected by the presence of reduced eGFR or albuminuria. Over 5 years all groups exhibited stable SF-6D and MCS scores but declining unadjusted PCS scores. PCS decline was greater for those with reduced eGFR, and remained significant after adjustment (−2.7 (−4.1 to −1.3) vs. −0.8 (−1.1 to −0.6, P < 0.01). Analyses according to CKD stages were essentially unchanged. Conclusion: Utility and mental QOL appears stable over 5 years, unaffected by time or markers of CKD health. Physical QOL appeared to deteriorate with time, especially for those with CKD, making it a more likely candidate assessment measure for intervention and health service evaluations.
AB - Aim: Assessing the impact of interventions on the patient experience requires measures that are plausibly responsive to change. In a community cohort of people with and without chronic kidney disease (CKD) markers at baseline, we aimed to evaluate change in commonly used measures of quality of life (QOL) over the passage of 5 years. Methods: Included were 6400 participants in the Australian Diabetes, Obesity and Lifestyle (AusDiab) surveys with baseline and 5-year CKD and QOL measures. Changes in SF-6D utility, and the Medical Outcomes Study 36-Item Short Form (SF-36) physical (PCS) and mental (MCS) component summary scores, were evaluated with regression analyses according to the baseline presence of reduced estimated glomerular filtration rate (eGFR) (CKD-Epidemiology Collaboration eGFR ≤60 m/min per 1.73 m 2 ) or albuminuria (urine albumin:creatinine ratio ≥3.4 mg/mmol). Results: At baseline, eGFR was reduced in 2.4% of participants and 5.1% had albuminuria. Participants with reduced eGFR had a lower SF-6D and PCS, and those with albuminuria a lower PCS, compared with those without, but the differences were explained by known confounders. MCS scores were not affected by the presence of reduced eGFR or albuminuria. Over 5 years all groups exhibited stable SF-6D and MCS scores but declining unadjusted PCS scores. PCS decline was greater for those with reduced eGFR, and remained significant after adjustment (−2.7 (−4.1 to −1.3) vs. −0.8 (−1.1 to −0.6, P < 0.01). Analyses according to CKD stages were essentially unchanged. Conclusion: Utility and mental QOL appears stable over 5 years, unaffected by time or markers of CKD health. Physical QOL appeared to deteriorate with time, especially for those with CKD, making it a more likely candidate assessment measure for intervention and health service evaluations.
UR - http://www.scopus.com/inward/record.url?scp=85064458028&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064458028&partnerID=8YFLogxK
U2 - 10.1111/nep.13445
DO - 10.1111/nep.13445
M3 - Article
C2 - 30039893
AN - SCOPUS:85064458028
SN - 1320-5358
VL - 24
SP - 605
EP - 614
JO - Nephrology
JF - Nephrology
IS - 6
ER -